Iron chelation therapy in myelodysplastic syndromes: where do we stand?

The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines

(2017) Peter L. Greenberg et al.   Journal of the National Comprehensive Cancer Network

NCCN Task Force: Transfusion and Iron Overload in Patients With Myelodysplastic Syndromes

(2017) Peter L. Greenberg et al.   Journal of the National Comprehensive Cancer Network

Myelodysplastic Syndromes

(2017) Peter L. Greenberg et al.   Journal of the National Comprehensive Cancer Network

Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS)

(2013) Amer M. Zeidan et al.   AMERICAN JOURNAL OF MEDICINE

Epidemiology of Myelodysplastic Syndromes

(2012) Xiaomei Ma   AMERICAN JOURNAL OF MEDICINE

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

(2012) F. Nolte et al.   ANNALS OF HEMATOLOGY

Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population

(2012) Massimo Breccia et al.   ANNALS OF HEMATOLOGY

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT

(2012) P Armand et al.   BONE MARROW TRANSPLANTATION

Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS

(2012) Norbert Gattermann   CURRENT PHARMACEUTICAL DESIGN

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox

(2012) Shohei Kikuchi et al.   FREE RADICAL BIOLOGY AND MEDICINE

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

(2012) N. Gattermann et al.   HAEMATOLOGICA

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

(2012) Alan F. List et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective toxicity towards myelodysplastic hematopoietic progenitors – Another rationale for iron chelation in MDS

(2012) E. Fibach et al.   LEUKEMIA RESEARCH

Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors

(2012) Vinod Pullarkat et al.   LEUKEMIA RESEARCH

Improved survival in MDS patients receiving iron chelation therapy – A matched pair analysis of 188 patients from the Düsseldorf MDS registry

(2012) Judith Neukirchen et al.   LEUKEMIA RESEARCH

Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes

(2012) Julia Hartmann et al.   LEUKEMIA RESEARCH

Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome

(2012) Alan E. Mast et al.   TRANSFUSION

Predicted costs of iron-chelators in myelodysplastic syndromes: A 10-year analysis based on actual prevalence and red cell transfusion rates

(2011) Senthilkumar Durairaj et al.   AMERICAN JOURNAL OF HEMATOLOGY

A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS

(2011) Aristoteles Giagounidis et al.   ANNALS OF HEMATOLOGY

Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes

(2011) Michel Delforge et al.   ANNALS OF HEMATOLOGY

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

(2011) Norbert Gattermann et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

(2011) A. J. Davidoff et al.   HAEMATOLOGICA

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

(2011) L. Malcovati et al.   HAEMATOLOGICA

Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome

(2011) Jaroslav Cermak et al.   HEMOGLOBIN

Iron-Chelating Therapy for Transfusional Iron Overload

(2011) Gary M. Brittenham   NEW ENGLAND JOURNAL OF MEDICINE

The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate

(2011) David P. Steensma   Current Hematologic Malignancy Reports

Controversies surrounding iron chelation therapy for MDS

(2010) Heather A. Leitch   BLOOD REVIEWS

Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload

(2010) E Ozyilmaz et al.   BONE MARROW TRANSPLANTATION

The struggle for iron - a metal at the host-pathogen interface

(2010) Manfred Nairz et al.   CELLULAR MICROBIOLOGY

Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

(2010) E. Messa et al.   HAEMATOLOGICA

Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes

(2010) H. Ghoti et al.   HAEMATOLOGICA

Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries

(2010) Stuart L. Goldberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Iron chelation therapy in MDS: Does it improve survival?

(2010) Heather A. Leitch   LEUKEMIA RESEARCH

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

(2010) Christian Rose et al.   LEUKEMIA RESEARCH

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

(2010) Norbert Gattermann et al.   LEUKEMIA RESEARCH

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes

(2010) Peter L. Greenberg et al.   LEUKEMIA RESEARCH

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

(2010) V. Santini et al.   LEUKEMIA RESEARCH

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review

(2010) Roberto Guariglia et al.   LEUKEMIA RESEARCH

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements

(2009) Angel F. Remacha et al.   ANNALS OF HEMATOLOGY

Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?

(2009) V. Pullarkat   BLOOD

Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children

(2009) J W Lee et al.   BONE MARROW TRANSPLANTATION

Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation

(2009) Anuj Mahindra et al.   BRITISH JOURNAL OF HAEMATOLOGY

Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders

(2009) Thomas E. Delea et al.   CURRENT MEDICAL RESEARCH AND OPINION

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study

(2009) E. P. Alessandrino et al.   HAEMATOLOGICA

Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation

(2009) Z.Y. Lim et al.   LEUKEMIA RESEARCH

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices

(2009) Anastasios Raptis et al.   TRANSFUSION

Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

(2009) H. A. Leitch et al.   Hematology-American Society of Hematology Education Program

Consensus statement on iron overload in myelodysplastic syndromes

(2008) John M. Bennett et al.   AMERICAN JOURNAL OF HEMATOLOGY

Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts

(2008) Cheng E. Chee et al.   AMERICAN JOURNAL OF HEMATOLOGY

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

(2008) Jelena M. Kao et al.   AMERICAN JOURNAL OF HEMATOLOGY

Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study

(2008) Georgia Metzgeroth et al.   ANNALS OF HEMATOLOGY

Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)

(2008) Uwe Platzbecker et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

(2008) M. A. Sanz et al.   BLOOD

ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy

(2008) J. K. C. Chan et al.   BLOOD

Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation

(2008) V Pullarkat et al.   BONE MARROW TRANSPLANTATION

Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment

(2008) Ashraf S Ibrahim et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform

(2008) P. Valent et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias

(2008) A. A. Di Tucci et al.   HAEMATOLOGICA

A pilot MRI study of organ specific hemosiderosis and functional correlation in Chinese patients with myelodysplasia and aplastic anemia with raised ferritin levels

(2008) WY Au et al.   HEMATOLOGICAL ONCOLOGY

Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes

(2008) Takahiro Suzuki et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

(2008) Norbert Gattermann   INTERNATIONAL JOURNAL OF HEMATOLOGY

Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

(2008) Mikkael A. Sekeres et al.   JNCI-Journal of the National Cancer Institute

Iron overload in myelodysplastic syndromes

(2008) Sameer Mahesh et al.   LEUKEMIA & LYMPHOMA

Iron overload in myelodysplastic syndromes: A Canadian consensus guideline

(2008) Richard A. Wells et al.   LEUKEMIA RESEARCH

Myelodysplasia paranoia: Iron as the new radon

(2008) David P. Steensma   LEUKEMIA RESEARCH

Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes

(2008) M. Cazzola et al.   Hematology-American Society of Hematology Education Program

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation

(2007) Philippe Armand et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION